In conversation with Dr. Brent Zanke

As the founder and chairman of ArcticDx, Dr. Brent Zanke has a five-star pedigree turning molecular diagnostics into personalized medicine.  An oncologist, geneticist and genetic epidemiologist, he was the principal investigator of a Genome Canada investment program called the ARCTIC project (Assessment of Risk for Colon Tumours in Canada).  The study came up with a [...]

Amgen gets rights to Array’s diabetes program

Array BioPharma has granted Amgen exclusive worldwide rights to its small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes. Under the accord, Array (NASDAQ:ARRY) will receive an upfront payment of $60 million (U.S.) and additional payments for certain clinical and commercial milestones, the [...]

Wex plans $34.5-million rights offering

Wex Pharmaceuticals (TSX:WXI) has filed for a rights offering to raise about $34.5-million, with proceeds earmarked to fund research and development, and for working capital. Under the plan, holders of restricted voting shares of Wex on Dec. 23 will receive rights to purchase 1.5 new shares at a subscription price of 13 cents.  The rights [...]

FDA clears path for ProMetic’s anemia drug

ProMetic Life Sciences (TSX:PLI) says it was “very excited by the outcome” of a meeting earlier this week with the FDA’s division of Medical Imaging and Hematology Products to discuss the regulatory pathway for the development of the company’s PBI-1402 drug. The FDA “acknowledged that PBI-1402 is a novel, first-in-class drug that differs, via its [...]

GeneNews targets $2-million private placement

GeneNews (TSX:GEN) plans to sell in a non-brokered private placement up to 4,444,444 new shares of the company at a price of 45 cents each to raise up to $2-million. Proceeds will be used for working capital, continued marketing of the ColonSentry test in Canada, and the commercial prelaunch of ColonSentry in the U.S., Europe [...]

Critical Outcome’s cancer drug continues positive track record

Critical Outcome Technologies (TSX-V:COT) has obtained positive results from new animal studies with its COTI-2 oral drug candidate, demonstrating efficacy as a single agent and in combination with first line therapies, and with low toxicity, in animal models of human cancers. In a statement, the company said COTI-2, as a single agent, demonstrated efficacy comparable [...]

Ottawa gives green light to TearLab osmolarity test for Dry Eye Disease

Health Canada has issued a medical device license for the TearLab Osmolarity System, which measures the osmolarity of human tears to aid in the diagnosis of Dry Eye Disease.  This clears TearLab Corp. (NASDAQ:TEAR; TSX:TLB) to immediately begin marketing the test to Canadian optometrists and ophthalmologists. The system “offers a rapid and very easy to [...]

Amorfix’s A4 test used successfully in study of EnVivo’s Alzheimer’s drug candidate

EnVivo Pharmaceuticals said today that, as part of a collaborative effort with Amorfix Life Sciences (TSX:AMF), its EVP-0962 drug candidate demonstrated in-vivo reduction of aggregated Abeta or Beta-amyloids in an aged transgenic model of Alzheimer’s disease. In a statement, closely held EnVivo of Watertown, Mass. said the study results were obtained using Amorfix’s A4 assay [...]

Warnex and Lakehead to develop new DNA database

Warnex Inc.’s PRO-DNA Services unit and the Paleo-DNA Laboratory of Lakehead University have received a total of $676,100 from the Northern Ontario Heritage Fund Corp. to develop a forensics database based on mitochondrial DNA. “Mitochondrial DNA testing is a powerful tool being used to solve criminal cases, including cold cases, as well as to prove [...]

AEterna’s missed Phase 3 gets ho-hum analyst reaction

Analysts are not surprised that Aeterna Zentaris’ cetrorelix drug candidate missed its primary endpoint in a Phase 3 clinical trial in Europe, matching the disappointing outcome of a similar pivotal trial in the U.S. earlier this year. RBC Capital Markets now expects AEterna (NASDAQ:AEZS; TSX:AEZ) to terminate the cetrorelix program and focus on its other [...]

« Previous Page — Next Page »